R&D News | pharmaphorum

News

New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

News

The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.

News

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.